Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma

Myra Langendonk(University Medical Center Groningen), Lydia Visser(University Medical Center Groningen)

International Journal of Molecular Sciences

November 9, 2022

10.3390/ijms232213751

Cited by 5

Related Papers

Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups

|JNCI Journal of the National Cancer Institute|2012|171

Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma

|Blood Cancer Journal|2022|20

A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas

|PLoS ONE|2019|15